Ann: Strategic Placement to Raise $3.5 million, page-29

Can I suggest people write to the Chairman and express their displeasure. He thinks he has done well:

“The support of these strategic investors is an endorsement of Orthocell’s science, business strategy and progress in commercialising it’s leading bone and nerve repair products, and the exciting outlook for the Company as it progresses approvals in new key jurisdictions like the US. The Board and I would like to welcome the new investors to the register.”

He did specifically say he was here to encourage "high quality investors" at the AGM, amongst other things:

"Paul and the team have done a great job recently in raising the profile of the Company with institutional investors through the initiation of coverage by two Sydney based broking firms. My role is to assist Paul and the team in consistently promoting the Orthocell story and increasing the percentage of stock held by high quality investors. I believe we present a compelling investment case, and we are starting to gain traction with some high-profile investors buying on market. There is more work to do, but we are clear on the path ahead to optimise the share register, and what it will take to drive upward pressure on the stock price."

You as existing shareholders and owners of the company are entitled to tell the stewards of your capital, you do not want his deemed "high quality" investors added at a discount as well as dilution effect - now if it was J&J buying in at a discount, with some nice upfront cash and milestone partnership payments, that would be a "high quality" investor we'd all accept those implications for.